Key Points
- Insider sale: General Counsel James Kasinger sold 1,040 CRISPR Therapeutics shares for approximately $51,230 at $49.26 per share. The transaction covered tax withholding tied to vested equity awards, reducing his holdings by 1.07% to 95,857 shares.
- Financial performance: CRISPR Therapeutics reported quarterly revenue of $10.18 million and a loss of $0.94 per share, while analysts expect a full-year loss of $4.48 per share. The stock opened at $51.52, below its 50-day and 200-day moving averages.
- Analyst outlook: Despite mixed ratings, including a sell rating and several neutral assessments, the stock has a consensus “Moderate Buy” rating and an average price target of $65.75, above its reported trading level.
CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) General Counsel James Kasinger sold 1,040 shares of the stock in a transaction on Wednesday, October 14th. The stock was sold at an average price of $49.26, for a total value of $51,230.40. Following the sale, the general counsel owned 95,857 shares of the company's stock, valued at approximately $4,721,915.82. This represents a 1.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
CRISPR Therapeutics Stock Performance
CRSP opened at $51.52 on Friday. CRISPR Therapeutics AG has a 1 year low of $44.12 and a 1 year high of $75.06. The company has a debt-to-equity ratio of 0.34, a current ratio of 17.85 and a quick ratio of 17.85. The stock has a fifty day moving average price of $55.07 and a 200 day moving average price of $53.24.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last issued its earnings results on Tuesday, June 30th. The company reported ($0.94) EPS for the quarter. CRISPR Therapeutics had a negative net margin of 3,368.72% and a negative return on equity of 24.39%. The firm had revenue of $10.18 million during the quarter. As a group, equities analysts expect that CRISPR Therapeutics AG will post -4.48 EPS for the current year.
Wall Street Analyst Weigh In
Several equities research analysts have recently issued reports on CRSP shares. Weiss Ratings reiterated a "sell (d-)" rating on shares of CRISPR Therapeutics in a report on Friday, July 17th. The Goldman Sachs Group reissued a "neutral" rating and issued a $55.00 price target on shares of CRISPR Therapeutics in a research note on Thursday, August 6th. Needham & Company LLC restated a "buy" rating and issued a $82.00 price objective on shares of CRISPR Therapeutics in a report on Monday, August 31st. William Blair raised shares of CRISPR Therapeutics to a "strong-buy" rating in a research report on Wednesday, September 23rd. Finally, UBS Group assumed coverage on shares of CRISPR Therapeutics in a research note on Thursday. They issued a "neutral" rating and a $52.00 target price for the company. Two research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, seven have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $65.75.
View Our Latest Analysis on CRISPR Therapeutics
Institutional Investors Weigh In On CRISPR Therapeutics
A number of large investors have recently bought and sold shares of CRSP. Canal Insurance CO bought a new position in CRISPR Therapeutics during the first quarter valued at about $1,670,000. Quantinno Capital Management LP lifted its position in shares of CRISPR Therapeutics by 613.5% in the first quarter. Quantinno Capital Management LP now owns 47,989 shares of the company's stock worth $2,283,000 after buying an additional 41,263 shares during the last quarter. KBC Group NV lifted its position in shares of CRISPR Therapeutics by 3,999.9% in the first quarter. KBC Group NV now owns 116,847 shares of the company's stock worth $5,558,000 after buying an additional 113,997 shares during the last quarter. Shah Wealth Advisors LLC acquired a new stake in shares of CRISPR Therapeutics in the second quarter worth about $3,767,000. Finally, Raiffeisen Bank International AG bought a new stake in shares of CRISPR Therapeutics during the 2nd quarter worth about $1,127,000. 69.20% of the stock is currently owned by institutional investors.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics AG (NASDAQ: CRSP) is a biotechnology company focused on developing gene-editing medicines based on CRISPR/Cas9 technology. The company aims to treat serious diseases by precisely modifying genetic material in patients' cells, with research programs spanning hematology, oncology, autoimmune diseases, and regenerative medicine.
Its lead product, CASGEVY (exagamglogene autotemcel), is a CRISPR/Cas9-based cell therapy developed with Vertex Pharmaceuticals. CASGEVY is approved in multiple markets, including the United States, United Kingdom, and European Union, for certain patients with sickle cell disease and transfusion-dependent beta thalassemia.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
